
Beryl Drugs Ltd Upgraded to Hold by MarketsMOJO on Improving Technicals and Valuation
2026-11-16 08:08:56Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 13 Nov 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a cautious but positive outlook for investors.
Read MoreBeryl Drugs Gains 3.70%: 2 Key Factors Driving the Week’s Momentum
2026-10-25 11:00:32Key Events This Week 19 Oct: Upgrade to Hold rating by MarketsMOJO citing improved technicals and valuation 21 Oct: New 52-week high reached at Rs.27.9 23 Oct: Week closes at Rs.24.69, up 3.70% vs Sensex down 3.75% Week Open Rs.23.81 Week Close ...
Read More
Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases
2026-10-20 08:16:44Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 19 Oct 2026. This change reflects a notable improvement in the company’s technical indicators and valuation metrics, despite flat recent financial performance. The upgrade is underpinned by a more bullish technical trend, attractive valuation ratios, and a stable financial trend, positioning the stock for cautious optimism amid a challenging market backdrop.
Read More
Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals
2026-10-14 08:09:58Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 13 Oct 2026. This shift reflects a complex interplay of technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling caution for investors despite some pockets of resilience in recent performance.
Read More
Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attracts Investors
2026-10-13 08:20:51Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 12 Oct 2026. This revision reflects a nuanced improvement across multiple parameters including technical indicators, valuation metrics, and financial trends, despite some lingering concerns over long-term fundamentals. The company’s recent performance and market positioning warrant a closer examination for investors seeking clarity on its prospects.
Read More
Beryl Drugs Ltd Upgraded to Hold as Technicals and Valuation Improve
2026-10-01 08:08:16Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 30 September 2026. This change reflects notable improvements in the company’s technical indicators and valuation metrics, despite flat recent financial performance. The upgrade highlights a cautiously optimistic outlook amid mixed fundamental signals and a strong market-beating return over the past year.
Read More
Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals
2026-09-29 08:09:10Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 28 Sep 2026. This change reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. Despite some positive technical signals and attractive valuation metrics, the company’s weak long-term fundamentals and flat recent financial performance have weighed heavily on the overall outlook.
Read More
Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases
2026-08-31 08:02:06Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 28 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite ongoing challenges in long-term fundamentals and market performance.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSENEWSPAPER PUBLICATION
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026
14-Nov-2026 | Source : BSEUNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026
Board Meeting Outcome for OUTCOME OF BOARD MEETING
14-Nov-2026 | Source : BSEOUTCOME OF BOARD MEETING
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available